Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development...

EGRX : 58.97 (-0.97%)
ATRS : 4.24 (-4.50%)
Antares Pharma Social Media Campaign for XYOSTED(R) Wins MarCom Platinum Award

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company") today announced that the Company's social media campaign for XYOSTED, has been honored with a 2019 MarCom Platinum Award. The award is the...

ATRS : 4.24 (-4.50%)
Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31 Annual Piper Jaffray Healthcare Conference on Tuesday December 3,...

ATRS : 4.24 (-4.50%)
REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to develop a novel, drug-device product...

ATRS : 4.24 (-4.50%)
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to develop a novel, drug-device product...

ATRS : 4.24 (-4.50%)
Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20,...

ATRS : 4.24 (-4.50%)
Antares Pharma: 3Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported third-quarter net income of $1 million, after reporting a loss in the same period a year earlier.

ATRS : 4.24 (-4.50%)
Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

Record Quarterly Revenue of $34.3 Million - Earnings Per Share of $0.01

ATRS : 4.24 (-4.50%)
Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet(TM) Needle-Free Delivery System

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or "Company") today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals ("Ferring") in connection with the previously...

ATRS : 4.24 (-4.50%)
Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019. Management...

ATRS : 4.24 (-4.50%)
Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th Annual Fall Scientific Meeting of the Sexual Medicine...

ATRS : 4.24 (-4.50%)
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September...

ATRS : 4.24 (-4.50%)
Teva Announces Availability of a Generic Equivalent of EpiPen Jr(R) (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr(R)(1) (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S....

TEVA : 10.20 (-3.95%)
ATRS : 4.24 (-4.50%)
Antares Pharma: 2Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $2.2 million in its second quarter.

ATRS : 4.24 (-4.50%)
Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue

ATRS : 4.24 (-4.50%)
Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Management...

ATRS : 4.24 (-4.50%)
Needle Free Drug Delivery Devices Market is expanding steadily at a CAGR of 9.90% till 2023, Noted TMR

Healthcare industry across the globe is booming due to increasing importance on saving life and ensuring every person to get adequate healthcare facilities. Governments are also taking significant and...

ATRS : 4.24 (-4.50%)
ZGNX : 54.98 (-2.85%)
Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or "the Company") today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC),...

ATRS : 4.24 (-4.50%)
HTGC : 14.41 (+0.28%)
Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday...

ATRS : 4.24 (-4.50%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar